Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. 

In this video, the company’s chief executive officer Bill Ketelbey provides an update on recent developments, R&D progress and expected newsflow.</p>

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment that occurs in chronic neurodegenerative and metabolic diseases. 

In this video, the company’s chief executive officer Bill Ketelbey provides an update on recent developments, R&D progress and expected newsflow.

<p>Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II XanADu trial results, only to rebound in October 2019 almost to per-XanADu levels after preliminary results from another clinical trial XanaHES were reported. XanaHES was designed as a Phase I safety trial to test high doses of Xanamem, but a smart trial design (exploratory cognitive endpoints included) and well-timed initiation led to the right results being reported at the right time. Actinogen will still need to complete its R&D programme and pinpoint further R&D direction. Until then, our updated valuation stands at A$131m or A$0.12/share (vs A$0.17/share previously).</p>

Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II XanADu trial results, only to rebound in October 2019 almost to per-XanADu levels after preliminary results from another clinical trial XanaHES were reported. XanaHES was designed as a Phase I safety trial to test high doses of Xanamem, but a smart trial design (exploratory cognitive endpoints included) and well-timed initiation led to the right results being reported at the right time. Actinogen will still need to complete its R&D programme and pinpoint further R&D direction. Until then, our updated valuation stands at A$131m or A$0.12/share (vs A$0.17/share previously).

Actinogen Medical - Well-timed XanaHES study saves the day

Australia

Actinogen Medical Limited operates as a biotechnology company. The Company focuses on the treatment of alzheimer's disease and mild cognitive impairment. Actinogen Medical develops a novel drug to treat the condition and other age-related neurodegenerative diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Actinogen Medical (ACW AU)

Actinogen Medical - Executive interview

Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment...

Edison Investment Research

Actinogen Medical - Well-timed XanaHES study saves the day

Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)